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Patients with second-stage human African trypanosomiasis
treated with eﬂornithine ( ) in 2003 in Kiri, southern n p 251
Sudan, had an adjusted relative risk of death of 0.2 and
experienced signiﬁcantly fewer cutaneous and neurological
adverse effects than did patients who were treated with me-
larsoprol in 2001 and 2002 ( ). n p 708
Human African trypanosomiasis (HAT) due to Trypanosoma
brucei gambiense remains a signiﬁcant public health problem
in some of the poorest countries of sub-Saharan Africa. Me-
larsoprol, an arsenical drug that has been used since 1949, is
still used for treating second-stage (or meningo-encephalitic–
stage) HAT in most areas of endemicity. This drug is highly
toxic, with acute reactive encephalopathyoccurringin5%–10%
of treated patients, resulting in a case-fatality rate of ∼50% [1].
Moreover, a dramatic increase in the rate of failure of treatment
has been noted in several endemic foci [2].
Eﬂornithine (diﬂuoromethylornithine [DFMO]), an inhib-
itor of ornithine decarboxylase developed in the 1980s, is the
only other drug registered for the treatment of second-stage
HAT. When it is administered at the recommendedintravenous
dose of 400 mg/kg per day for 14 days, the limited published
data have shown that is has a high efﬁcacy and is associated
with case-fatality rates of 2%–3% [3, 4]. Although the drug
was initially unavailable because of irregular production and
high pricing, a recent 5-year donation agreement between the
World Health Organization (WHO) and Aventis Pharma has
made it widely available for use in the ﬁeld.
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At the Me ´decins Sans Frontie `res sleeping sickness treatment
center in Kiri, Kajo-Keji County, southern Sudan, patientswith
second-stage HAT were treated with intravenous melarsoprol
at a dosage of 2.2 mg/kg per day and oral prednisone for 10
days from June 2000 to December 2002. This treatment was
changed in January 2003 to a course of intravenous DFMO
administered at a dosage of 400 mg/kg per day divided into
four 3-h infusions for 14 days. Because of decreased bioavail-
ability of DFMO for children aged !12 years [5], the daily dose
was increased to 600 mg/kg for this age category. Follow-up
visits were scheduled at 6, 12, and 24 months after the end of
treatment. We retrospectively reviewed outcomes during this
period, to compare case-fatality rates, adverse-effects, and the
efﬁcacy of melarsoprol and DFMO.
Diagnosis and clinical staging followed a methodology that
has been described elsewhere [6]. Personal, laboratory, and
treatment data, including adverse effects and outcomes, were
recorded on standardized patients’ charts and entered into
YoTryp (Microsoft), a Microsoft Access–based software specif-
ically designed to monitor the program. Most adverse effects
were graded as benign to moderate (grade 1) or severe (grade
2). All patients’ charts were reviewed, and errors werecorrected
by one of the authors (F.C.) during several ﬁeld visits.
A total of 1376 patients with second-stage HAT were ad-
mitted between June 2000 and December 2003. Three hundred
twenty-four patients who were treated during the initial phase
of the project (June 2000–December 2000) were excluded from
analysis because they were at a more advanced stage of disease,
which resulted in a higher case-fatality rate. An additional 93
patients were also excluded from analysis: 46 patients who had
been previously treated for second-stage illness, 15 who had
been screened but not treated, and 32 who had been treated
with pentamidine or other drugs. Of the 959 remaining pa-
tients, we compared the characteristics of 708 patients treated
with melarsoprol in 2001 and 2002 with characteristics of the
251 patients treated with DFMO in 2003.
Baseline characteristics such as sex, residential status, mode
of screening, presence of cervical lymph nodes, and CSF WBC
count differed between the 2 cohorts (table 1). Twenty-ﬁve
patients (3.5%) died during melarsoprol treatment (because of
acute reactive encephalopathy in 92% of cases), whereas only
2 patients (0.8%) who were treated with DFMO died, which
is a signiﬁcant difference (table 2). On the basis of the number
of treatment days before death, we used Cox proportional haz-
ard regression models to adjust for differences in baseline char-
acteristics. After adjusting for sex, residential status, mode ofBRIEF REPORT • CID 2005:41 (1 September) • 749
Table 1. Baseline characteristics of patients with second-stage human Af-
rican trypanosomiasis treated with diﬂuoromethylornithine (DFMO) and me-





(n p 708) P
General
Age .59
Mean   SD 25   15 25   15
Range 1–75 0.5–85
Sex !.001
Male 161 (64) 346 (49) …
Female 90 (36) 362 (51) …
Residential status !.001
Resident of Kajo-Keji County 158 (63) 477 (67) …
Resident of other Sudanese county 36 (14) 24 (3) …
Displaced Sudanese 48 (19) 167 (24) …
Migrant Sudanese 9 (4) 34 (5) …
Non-Sudanese and/or unknown 0 6 (1) …
Mode of screening !.001
Passive 118 (47) 526 (74) …
Active 133 (53) 182 (26) …
Laboratory
Presence of a cervical lymph node 145 (58) 359 (51) .047
Positive LN puncture examination ﬁnding 132 (91) 315 (88) .29
Blood concentration technique
a .11
Positive 83 (33) 260 (37) …
Negative 36 (14) 128 (18) …
Not done 132 (53) 320 (45) …
Trypanosomes in CSF 99 (39) 297 (42) .49
CSF WBC count, cells/mL .031
3–19 63 (25) 188 (27) …
20–99 73 (29) 259 (37) …
100 115 (46) 261 (37) …
Diagnostic classiﬁcation .48
No previous treatment 244 (98) 678 (96) …
Relapse after ﬁrst stage of treatment 6 (2) 28 (4) …
NOTE. Data shown are no. (%) of patients, unless otherwise indicated.
a Either microhematocrit concentration technique or quantitative buffy coat analysis were
performed, depending on their availability. A positive ﬁnding indicates thattrypanosomeswere
found in the blood, and a negative ﬁnding indicates that trypanosomes were not found in the
blood.
screening,presenceof cervicallymphnodes,andCSFcellcount,
the relative risk of death following DFMO treatment was 0.20
(95% CI, 0.04–0.89).
Acute reactive encephalopathy occurred in 80 patients
(11.3%) treated with melarsoprol, but in only 1 patient (0.4%)
treated with DFMO. Moreover, patients treated with melar-
soprol were more likely to suffer from fever,hypertension,mac-
ular rash, severe headaches, peripheral neuropathy, andtremor.
Diarrhea was more frequent in the cohort treated with DFMO,
but the occurrence of severe diarrhea among patients in both
cohorts was comparable. Simple convulsions occurred in 7 pa-
tients (2.8%) treated with DFMO. Hemoglobin and WBC
counts were measured both before and at the end of treatment
in a subset of 184 patients treated with DFMO. We found no
statistical differences between pretreatment and posttreatment
hemoglobin levels (pretreatment median,11.7g/dL[range,6.7–
18.3 g/dL]; posttreatment median, 11.7 g/dL [range, 6–15.3
g/dL]; ) and WBC counts (pretreatment median, 7350 P p .96
cells/mm
3 [range, 3300–21,000 cells/mm
3]; posttreatment me-
dian, 7450 cells mm
3 [range, 2900–28,500 cells/mm
3]; P p
). .98
The rates of patient attendance to posttreatment follow-up
visits were 64% at 6 months after treatment and 46% at 12
months after treatment. There were 9 relapses (3.6%) and 1750 • CID 2005:41 (1 September) • BRIEF REPORT
Table 2. Comparison of outcomes for patients with second-
stage human African trypanosomiasis treated with diﬂuorome-








(n p 708) P
Mortality during treatment 2 (0.8) 25 (3.5) .024
Adverse effects of treatment
Fever 27 (10.8) 218 (32.3) !.001
Hypotension 0 (0.0) 6 (0.9) .13
Hypertension
All 8 (3.2) 48 (7.3) .02
Severe
a 0 (0.0) 17 (2.4) .013
Macular rash
All 1 (0.4) 49 (7.5) !.001
Severe
b 1 (0.4) 18 (2.5) .036
Bullous rash 0 (0.0) 4 (0.6) .22
Jaundice 0 (0.0) 8 (1.2) .08
Diarrhea
All 52 (20.9) 68 (10.3) !.001
Severe
c 4 (1.6) 18 (2.5) .39
Headaches
All 105 (42.2) 270 (39.7) .5
Severe
b 0 (0.0) 111 (15.7) !.001
Peripheral neuropathy
All 5 (2) 78 (11.8) !.001
Severe
d 0 (0.0) 12 (1.7) .038
Tremor
All 6 (2.4) 149 (22.7) !.001
Severe
e 0 (0.0) 18 (2.5) .011
Acute reactive encephalopathy
f
All 1 (0.4) 80 (11.3) !.001
Grade 1 0 (0.0) 21 (3) .006
Grade 2 1 (0.4) 59 (8.3) !.001
NOTE. Data shown are no. (%) of patients, unless otherwise indicated.
a Severity is deﬁned as systolic blood pressure of 1180 mm Hg and/or
diastolic blood pressure of 1100 mm Hg.
b Severity is deﬁned as an event leading to interruption of treatment.
c Severity is deﬁned as bloody diarrhea and/or signs of dehydration.
d Severity is deﬁned as an event leading to motor weakness, walking dis-
ability, and/or interruption of treatment.
e Severity is deﬁned as an event impairing simple activities.
f Grade 1 acute reactive encephalopathy is deﬁned as new onset of psy-
chosis during treatment. Grade 2 acute reactive encephalopathy is deﬁned as
prolonged or repeated convulsions (status epilepticus) or rapid deterioration
of the state of consciousness (with a Glasgow Coma Score of 8).
death (0.4%) in the DFMO group ( ), and there were n p 249
16 relapses (2.3%) and 6 deaths (0.9%) in the melarsoprol
group ( ) during the 12-month follow-up period. Post- n p 683
treatment relapse and death rates after treatment with DFMO
and melarsoprol were statistically comparable ( and P p .29
, respectively). P p .46
This retrospective analysis shows that 14 days of therapywith
intravenous DFMO resulted in fewer deaths and severe adverse
effects thandid 10 days oftherapywithintravenousmelarsoprol
for the treatment of second-stage HAT. Moreover, we found
no evidence of increased death or relapse rates within 12
months after the end of DFMO treatment.
The nonrandomized nature of this study, despite statistical
adjustment for differences in baseline characteristics,couldpre-
clude any deﬁnitive conclusion. However, we believeourresults
are valid. A fairly large number of patients were analyzed, and
all were treated in comparable conditions. Secondly, risk of
death was minimized in the melarsoprol cohort by excluding
patients who had been treated during the ﬁrst 7 months of the
program. Moreover, the proportion of patients with a CSF
WBC count of 1100 cells/mL, a marker of both disease severity
and increased risk of treatment failure [3, 7, 8], was higher in
the DFMO cohort.
The case-fatality rate for the DFMO cohort is the lowest
reported in the literature among patients treated for second-
stage HAT. This excellent safety record has been conﬁrmed in
other treatment centers in southern Sudan, where DFMO is
used as ﬁrst-line treatment of second-stage illness. Of 3178
patients treated by Malteser (Yei County) and Me ´decins Sans
Frontie `res (Mundri, Maridi and Kajo-Keji Counties) between
September 2001 and December 2004, the overall case-fatality
rate was 1%. Melarsoprol-induced acute reactive encephalop-
athy is a tragedy that generally takes patients and care-givers
by surprise and cannot be efﬁciently prevented. In contrast,
severe catheter-related bacterial infections, whicharefrequently
reported as a cause of complications in patients treated with
DFMO [3], were efﬁciently prevented in our program by pro-
viding adequate nursing care, such as the systematic changing
of intravenous catheters every 48 h, the use of sterile gauzes
around catheter puncture wounds, the application of single-
use sterile caps between infusions, and the daily surveillance
and early treatment of phlebitis and deep tissue infections [9].
After this improved nursing protocol was introduced in April
2003 for patients treated with DFMO, the incidences of phle-
bitis and deep-tissue bacterial infection decreased from 43% to
6.3% ( ) and from 1.9% to 0.7% ( ), respectively. P ! .001 P p .4
On the basis of these results, we recommend DFMO as the
treatment of choice for second-stage HAT, not only in areas
where treatment with melarsoprol has high failure rates (i.e.,
where it is currently the only option), but in all endemic areas
where adequate nursing care can be provided. Although the
lack of trained medical staff in many remote health care centers
and the insufﬁcient ﬁnancial and technical logistic capacities
in most countries of endemicity represent obstacles for the
universal use of DFMO, we observed that the increasednursing
workload caused by treatment with DFMO (e.g., the prepa-
ration of infusions and the management of catheters) was at
least partially compensated by the decreased amount of workBRIEF REPORT • CID 2005:41 (1 September) • 751
required to manage adverse effects due to treatment with
melarsoprol.
Nevertheless, a 14-day course of intravenous DFMO mono-
therapy is not a long-term solution. This regimen is compli-
cated to administer, it is potentially less effective in areas with
a high prevalence of HIV infection (DFMO is trypanostatic),
and it could lead to the development of parasite resistance. In
the short term, existing drugs should be studiedincombination
to simplify treatment and shorten its duration and to protect
against resistance [10]. To this end, a multicenter study of a
shorter course of intravenous DFMO administered twice per
day with a course of oral nifurtimox is underway. Although
this regimen is suboptimal, it remains the only possible ap-
proach, because the research pipeline for new drugs against
second-stage HAT is empty. Even the future of DFMO is fragile,
given that the donation agreement between the WHO and Av-
entis Pharma will soon expire. DFMO production must be
ensured, and the development of new drugs must be promoted
for the treatment of this neglected and devastating sickness.
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